Conversation with The Cancer Letter

Conversation with The Cancer Letter

OHSU Knight Cancer Institute splits leadership role in two: (1) CEO and (2) center director
Conversation with The Cancer Letter

OHSU Knight Cancer Institute splits leadership role in two: (1) CEO and (2) center director
Eight NCI-designated centers believe the top job is too big for one person

A previous version of this story stated incorrectly that seven institutions split the role of director in two. The original list omitted Fox Chase Cancer Center. Read more.Slowly, over the past two decades, at least eight major cancer centers have changed their organizational structures, splitting the job of the cancer center director into two boxes on the org chart: (1) the chief executive, and (2) the scientist in charge of the NCI Cancer Center Support Grant.
FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC
Conversation with The Cancer LetterRegulatory News

FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC
Pooled analysis finds correlations between early endpoints and OS in ICI trials

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.
University of Maryland’s Owonikoko: What it means to be a Black director of an NCI-designated cancer center
Black History MonthConversation with The Cancer Letter

University of Maryland’s Owonikoko: What it means to be a Black director of an NCI-designated cancer center

A month after reporting to work in the top job at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Taofeek K. Owonikoko reflected on the obligations that come with being a Black director of an NCI-designated cancer center.
Shikha Jain, Shea Holman: It’s time for NIH to be transparent about how misconduct cases are handled
Conversation with The Cancer Letter

Shikha Jain, Shea Holman: It’s time for NIH to be transparent about how misconduct cases are handled

NIH has until Feb. 20 to comply with a congressional subpoena that directs NIH Director Monica Bertagnolli to produce internal documents, including reports and whistleblower complaints that could shed light on whether NIH is adequately responding to complaints of workplace misconduct and sexual harassment.